acetylcysteine has been researched along with Kahler Disease in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (60.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, SJ; Jung, JH; Kim, B; Kim, JH; Kim, SH; Lee, HJ; Sohn, EJ; Sook, SH | 1 |
| Choi, S; Kim, J; Saxena, N; Singh, AK; Singh, I; Won, JS | 1 |
| Bible, KC; Isham, CR; Tibodeau, JD | 1 |
| Bera, S; Choudhury, A; Dispenzieri, A; Goel, A; Greiner, S; Russell, SJ; Spitz, DR | 1 |
| Li, J; Wu, XM; Zhang, DY | 1 |
| Abe, M; Amou, H; Fujii, S; Harada, T; Hiasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Oda, A; Ozaki, S; Takeuchi, K; Watanabe, T | 1 |
| Ai, G; Han, Y; Hou, J; Meng, X; Shao, Y; Shi, J; Tao, Y; Wei, R; Wu, X; Zhan, F; Zheng, J | 1 |
| Adamo, L; Amato, G; Anastasi, G; Buccheri, S; Cavalli, M; Chiarenza, A; Conticello, C; De Maria, R; Di Raimondo, F; Giuffrida, R; Giustolisi, R; Gulisano, M; Lombardo, L; Martinetti, D; Parrinello, N | 1 |
| Choi, HI; Chung, KJ; Kim, HJ; Lee, DS; Lee, IK; Lee, TH; Park, BJ; Ren, L; Yang, HY; Yang, U | 1 |
| Schenkein, D | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Li, G; Mitsiades, C; Mitsiades, N; Munshi, N; Podar, K; Sattler, M | 1 |
| Chen, YB; Ding, SQ; Fu, WJ; Hou, J; Kong, XT; Wang, DX; Yuan, ZG | 1 |
| Dai, Y; Grant, S; Pei, XY | 1 |
| Adachi, M; Hayashi, T; Imai, K; Ishida, T; Kawamura, R; Sakamoto, H; Shinomura, Y; Wang, W | 1 |
| Blau, IW; Busse, A; Driessen, C; Keilholz, U; Kraus, M; Na, IK; Rietz, A; Scheibenbogen, C; Thiel, E | 1 |
| Caligaris-Cappio, F; Cozza, S; Ferrarini, M; Nerini-Molteni, S; Sitia, R | 1 |
| Kayano, T; Kubota, H; Kurimoto, M; Ohta, T; Yanagi, H; Yokota, S; Yura, T | 1 |
| Briehl, MM; Dorr, RT; Dvorakova, K; Payne, CM; Tome, ME; Waltmire, CN | 1 |
| Bahlis, NJ; Boise, LH; Dalton, WS; Grad, JM; Oshiro, MM; Reis, I | 1 |
| Choi, I; Kang, HS | 1 |
2 review(s) available for acetylcysteine and Kahler Disease
| Article | Year |
|---|---|
[Classification and synthesis of ubiquitin-proteasome inhibitor].
Topics: Acetylcysteine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Dipeptides; Humans; Multiple Myeloma; Peptides, Cyclic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2009 |
Proteasome inhibitors in the treatment of B-cell malignancies.
Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Cell Cycle Proteins; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzymes; Gene Expression Regulation; Hodgkin Disease; Humans; Leukemia, B-Cell; Leupeptins; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Oncogene Proteins; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Substrate Specificity; Transcription Factors; Treatment Outcome | 2002 |
18 other study(ies) available for acetylcysteine and Kahler Disease
| Article | Year |
|---|---|
Reactive oxygen species-mediated activation of AMP-activated protein kinase and c-Jun N-terminal kinase plays a critical role in beta-sitosterol-induced apoptosis in multiple myeloma U266 cells.
Topics: Acetyl-CoA Carboxylase; Acetylcysteine; AMP-Activated Protein Kinases; Anthracenes; Apoptosis; Caspase 3; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclooxygenase 2; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Multiple Myeloma; Phosphorylation; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Sitosterols | 2014 |
Regulation of STAT3 and NF-κB activations by S-nitrosylation in multiple myeloma.
Topics: Acetylcysteine; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Mice; Multiple Myeloma; NF-kappa B; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2017 |
Annatto constituent cis-bixin has selective antimyeloma effects mediated by oxidative stress and associated with inhibition of thioredoxin and thioredoxin reductase.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Bixaceae; Carotenoids; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Glutathione; Humans; Multiple Myeloma; Oxidation-Reduction; Oxidative Stress; Phytotherapy; Plant Extracts; Reactive Oxygen Species; Seeds; Thioredoxin-Disulfide Reductase; Thioredoxins | 2010 |
Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis.
Topics: Acetylcysteine; Animals; Apoptosis; Blotting, Western; Bone Marrow Cells; Combined Modality Therapy; Dexamethasone; Enzyme-Linked Immunosorbent Assay; Hematopoiesis; Interleukin-6; Mice; Mice, Inbred C57BL; Mitochondria; Multiple Myeloma; Oxidative Stress; Plasma Cells; Polyethylene Glycols; Radiation Tolerance; Radiation-Protective Agents; Reactive Oxygen Species; Stromal Cells; Superoxide Dismutase; Tumor Cells, Cultured | 2010 |
Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Antioxidants; Ascorbic Acid; Autophagy; Boronic Acids; Bortezomib; Cell Line; Endoplasmic Reticulum; Free Radical Scavengers; Multiple Myeloma; Neuroprotective Agents; Peripheral Nervous System Diseases; Pyrazines; Rats; Schwann Cells | 2011 |
Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I.
Topics: Acetylcysteine; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Cytotoxicity, Immunologic; Down-Regulation; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Multiple Myeloma; Proteasome Inhibitors | 2011 |
Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Copper; Disulfiram; Enzyme Inhibitors; Free Radical Scavengers; Humans; Leukemia, Myeloid, Acute; Membrane Potentials; Mitochondrial Membranes; Multiple Myeloma; Oxidative Stress; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Reactive Oxygen Species | 2012 |
The role of peroxiredoxin V in (-)-epigallocatechin 3-gallate-induced multiple myeloma cell death.
Topics: Acetylcysteine; Apoptosis; Catechin; Cell Line, Tumor; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Humans; JNK Mitogen-Activated Protein Kinases; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Peroxiredoxins; Phosphorylation; Plasma Cells; Reactive Oxygen Species; Signal Transduction; Syndecan-1 | 2011 |
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.
Topics: 2-Methoxyestradiol; Acetylcysteine; Antioxidants; Apoptosis; Complement Membrane Attack Complex; Complement System Proteins; Cytochrome c Group; Dexamethasone; Drug Resistance; Estradiol; Glycoproteins; Humans; Membrane Potentials; Mitochondria; Multiple Myeloma; Signal Transduction; Superoxides; Tumor Cells, Cultured | 2003 |
[Mechanism of arsenic trioxide-induced cytotoxicity on multiple myeloma cells].
Topics: Acetylcysteine; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Division; Cell Survival; Drug Interactions; Glutathione; Humans; Multiple Myeloma; Oxides; Tumor Cells, Cultured; Vitamin K 3 | 2003 |
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytosol; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intracellular Membranes; Membrane Glycoproteins; Membrane Potentials; Mitochondria; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oxidative Stress; Oxygen; Protease Inhibitors; Proteins; Proteoglycans; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Sodium Oxybate; Syndecan-1; Syndecans; Tumor Suppressor Proteins; Vorinostat; X-Linked Inhibitor of Apoptosis Protein | 2004 |
Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity.
Topics: Acetylcysteine; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Apoptosis; Catalase; Cell Survival; Enzyme Inhibitors; Humans; Multiple Myeloma; Onium Compounds; Oxidative Stress; Reactive Oxygen Species; Sesquiterpenes | 2006 |
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.
Topics: Acetylcysteine; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Endopeptidases; Drug Screening Assays, Antitumor; Humans; Interferon-gamma; Lymphoma; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Subunits; Pyrazines | 2008 |
Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib.
Topics: Acetylcysteine; Activating Transcription Factor 4; Antineoplastic Agents; Antioxidants; Boronic Acids; Bortezomib; Cell Death; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glutathione; Homeostasis; Humans; Multiple Myeloma; Neoplasm Proteins; Oxidation-Reduction; Protease Inhibitors; Pyrazines; Transcription Factor CHOP; Tumor Cells, Cultured | 2008 |
Proteasome-dependent degradation of cytosolic chaperonin CCT.
Topics: Acetylcysteine; Adenosine Triphosphatases; Animals; Cell Division; Chaperonin Containing TCP-1; Chaperonins; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Cytosol; Enzyme Stability; Female; Kinetics; Ligases; Mammary Neoplasms, Experimental; Mice; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Temperature; Thermodynamics; Tumor Cells, Cultured; Ubiquitin-Activating Enzymes; Ubiquitin-Protein Ligases | 2000 |
Induction of mitochondrial changes in myeloma cells by imexon.
Topics: Acetone; Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Cytochrome c Group; DNA Damage; DNA, Mitochondrial; Electron Transport Complex II; Flow Cytometry; Hexanones; Humans; Leukemia, Promyelocytic, Acute; Lymphocytes; Membrane Potentials; Microscopy, Electron; Mitochondria; Multienzyme Complexes; Multiple Myeloma; Oxidative Stress; Oxidoreductases; Polymerase Chain Reaction; Reactive Oxygen Species; Succinate Dehydrogenase; Thiophenes; Tumor Cells, Cultured | 2001 |
Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Death; Drug Synergism; Glutathione; Humans; Hydrogen Peroxide; Multiple Myeloma; Oxides; Plasma Cells; Superoxides; Tumor Cells, Cultured | 2001 |
Protein phosphatase 2A modulates the proliferation of human multiple myeloma cells via regulation of the production of reactive oxygen intermediates and anti-apoptotic factors.
Topics: 3T3 Cells; Acetylcysteine; Animals; Antioxidants; Apoptosis; Cell Division; Enzyme Inhibitors; Gene Expression; Glutathione; Humans; Interleukin-6; Intracellular Fluid; Mice; Multiple Myeloma; NF-kappa B; Okadaic Acid; Phosphoprotein Phosphatases; Protein Phosphatase 2; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Transfection; Tumor Cells, Cultured | 2001 |